| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
10,11-Dihydrocarbamazepine exhibits antagonist activity at both the human 5HT3A and P2X4 receptors. It inhibits serotonin-induced inward Na+ current in HEK293 cells and ATP-induced cytosolic calcium influx in human 1321N1 cells. It also shows weak inhibitory effects on recombinant human SIRT2 and SIRT1.
|
|---|---|
| ln Vitro |
10,11-Dihydrocarbamazepine, the active metabolite of oxycarbazepine, is produced in the liver through its metabolism. An antiepileptic medication (AED) called oxycarbazepine is used either as a monotherapy or as an adjuvant treatment to treat partial seizures[1]. When determining the amount of 10,11-dihydrocarbamazepine in pharmaceutical formulations using liquid chromatography (LC), 10,11-dihydrocarbamazepine can be utilized as a reference standard[1].
10,11-Dihydrocarbamazepine inhibits serotonin-induced inward Na+ current in HEK293 cells at concentrations of 10 µM or higher, with inhibition not exceeding 50%. For the P2X4 receptor, it achieves 35% inhibition at 100 µM after a 30-minute preincubation, with an IC50 greater than 100,000 nM. It shows less than 25% inhibition of SIRT2 and SIRT1 at 50 µM. |
| ln Vivo |
10,11-Dihydrocarbamazepine is the active metabolite of oxcarbazepine and is responsible for its anticonvulsant effects in vivo. It modulates neuronal firing and neurotransmitter release to control seizures. As an active metabolite, it contributes to the therapeutic efficacy of oxcarbazepine in treating partial seizures.
|
| Enzyme Assay |
In vitro receptor binding assays are performed by incubating 10,11-Dihydrocarbamazepine with HEK293 cells expressing human 5HT3A receptors or 1321N1 cells expressing P2X4 receptors. For 5HT3A, serotonin-induced inward Na+ current is measured using patch-clamp electrophysiology. For P2X4, ATP-induced cytosolic calcium influx is measured using a Fluo-4 AM dye-based fluorescence assay. SIRT1/2 inhibition is assessed using a homogeneous fluorescent deacetylase assay with ZMAL as substrate.
|
| Cell Assay |
For in vitro cell assays, HEK293 cells or 1321N1 cells are cultured in appropriate media and treated with 10,11-Dihydrocarbamazepine at concentrations ranging from 1-100 µM. Receptor-mediated ion flux or calcium signaling is measured using fluorescence-based or electrophysiological techniques. Cell viability is assessed to determine compound cytotoxicity. The compound's effects on receptor antagonism are quantified by measuring inhibition of agonist-induced responses.
|
| Animal Protocol |
For in vivo animal studies, 10,11-Dihydrocarbamazepine is typically administered to rodents via oral gavage or intraperitoneal injection. As the active metabolite of oxcarbazepine, its anticonvulsant efficacy is evaluated in seizure models. Blood and brain tissue samples are collected to measure drug concentrations by LC-MS/MS. The compound's pharmacokinetic profile and tissue distribution are assessed to understand its role in oxcarbazepine's therapeutic effects.
|
| ADME/Pharmacokinetics |
10,11-Dihydrocarbamazepine (MW 238.28) is soluble in DMSO (55 mg/mL). It is stable as a powder at -20°C for 3 years and in solvent at -80°C for 1 year. In vivo formulations may use 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline. As a metabolite of oxcarbazepine, it is produced via hepatic reduction and circulates systemically to exert anticonvulsant effects.
|
| Toxicity/Toxicokinetics |
10,11-Dihydrocarbamazepine is for research use only. No specific toxicity data are available for this compound. As the active metabolite of the approved antiepileptic drug oxcarbazepine, its safety profile is expected to be consistent with that of the parent drug at therapeutic concentrations. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Courtney Hunek, et al. Measurement of 10,11-dihydro-10-hydroxy-carbamazepine in serum and plasma by high-performance liquid chromatography. Clin Chem Lab Med. 2008;46(10):1429-33.
|
| Additional Infomation |
See also: Carbamazepine (note moved to).
10,11-Dihydrocarbamazepine (CAS# 3564-73-6) is the primary active metabolite of oxcarbazepine, an antiepileptic drug used for partial seizures. It has not been approved as a standalone therapeutic agent but is used as a pharmaceutical intermediate and reference standard. The compound is classified as a drug metabolite and reference standard in the metabolic enzyme/protease pathway. It is widely used in neurological research and pharmaceutical quality control. |
| Molecular Formula |
C15H14N2O
|
|---|---|
| Molecular Weight |
238.28
|
| Exact Mass |
238.11
|
| CAS # |
3564-73-6
|
| Related CAS # |
10,11-Dihydrocarbamazepine; 3564-73-6
|
| PubChem CID |
19099
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
394.5±52.0 °C at 760 mmHg
|
| Melting Point |
205-210ºC
|
| Flash Point |
192.4±30.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.645
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
294
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(N([H])[H])N1C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C([H])([H])C2=C([H])C([H])=C([H])C([H])=C12
|
| InChi Key |
PHNLCHMJDSSPDQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-8H,9-10H2,(H2,16,18)
|
| Chemical Name |
5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~419.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (10.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1967 mL | 20.9837 mL | 41.9674 mL | |
| 5 mM | 0.8393 mL | 4.1967 mL | 8.3935 mL | |
| 10 mM | 0.4197 mL | 2.0984 mL | 4.1967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
